NCT02189733View on ClinicalTrials.gov

Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

Caplacizumab

Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT02189733 - Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab. | Biotech Hunter | Biotech Hunter